A Prescription for Decline: Pfizer's Dependence on Blockbuster Drugs Pfizer, one of the world's largest pharmaceutical companies, faces a pressing issue that has been developing over years.
The company's reliance on aging blockbuster drugs is dwindling, and its efforts to diversify have failed to yield significant results.
This trend is evident in the recent quarterly earnings report, which shows Pfizer beating profit estimates due largely to strong demand for blood thinner Eliquis.